Pfizer Inc (PFE)
25.38
-0.04
(-0.14%)
USD |
NYSE |
Apr 18, 16:00
25.36
-0.02
(-0.10%)
After-Hours: 20:00
Pfizer Gross Profit (TTM): 33.54B for Dec. 31, 2023
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 33.54B |
September 30, 2023 | 41.50B |
June 30, 2023 | 54.11B |
March 31, 2023 | 63.71B |
December 31, 2022 | 65.99B |
September 30, 2022 | 65.45B |
June 30, 2022 | 62.98B |
March 31, 2022 | 55.78B |
December 31, 2021 | 50.47B |
September 30, 2021 | 45.08B |
June 30, 2021 | 39.25B |
March 31, 2021 | 35.38B |
December 31, 2020 | 33.17B |
September 30, 2020 | 25.85B |
June 30, 2020 | 27.66B |
March 31, 2020 | 30.31B |
December 31, 2019 | 32.85B |
September 30, 2019 | 31.79B |
June 30, 2019 | 32.32B |
March 31, 2019 | 32.18B |
December 31, 2018 | 31.84B |
September 30, 2018 | 41.94B |
June 30, 2018 | 41.66B |
March 31, 2018 | 41.35B |
December 31, 2017 | 41.32B |
Date | Value |
---|---|
September 30, 2017 | 41.29B |
June 30, 2017 | 40.92B |
March 31, 2017 | 40.66B |
December 31, 2016 | 40.50B |
September 30, 2016 | 40.72B |
June 30, 2016 | 40.63B |
March 31, 2016 | 40.33B |
December 31, 2015 | 39.20B |
September 30, 2015 | 38.98B |
June 30, 2015 | 39.11B |
March 31, 2015 | 39.75B |
December 31, 2014 | 40.03B |
September 30, 2014 | 40.38B |
June 30, 2014 | 40.74B |
March 31, 2014 | 41.16B |
December 31, 2013 | 42.00B |
September 30, 2013 | 42.37B |
June 30, 2013 | 42.66B |
March 31, 2013 | 43.52B |
December 31, 2012 | 45.51B |
September 30, 2012 | 44.24B |
June 30, 2012 | 46.80B |
March 31, 2012 | 48.12B |
December 31, 2011 | 48.79B |
September 30, 2011 | 51.27B |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
25.85B
Minimum
Sep 2020
65.99B
Maximum
Dec 2022
43.54B
Average
39.25B
Median
Jun 2021
Gross Profit (TTM) Benchmarks
Amgen Inc | 19.74B |
Gilead Sciences Inc | 20.62B |
Johnson & Johnson | 63.01B |
Viking Therapeutics Inc | -- |
Moderna Inc | 2.061B |